Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo

Neoplasia

Volumn 9, Issue 4, 2007, Pages 322-331

  Vandyke, Kate ^a,b   White, Melanie Y ^c   Nguyen Khuong, Terry ^c   Ow, Kim ^a,b   Luk, Sharon C W ^d   Kingsley, Elizabeth A ^a,b   Rowe, Alexandra ^a,b   Pang, Shiu Fun ^d   Walsh, Bradley J ^c   Russell, Pamela J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Minomic Pty Ltd   (Australia)

^d CK Life Sciences Int'l Holdings Inc   (Hong Kong)

Author keywords

Clonogenic assays; G2M block; Lymph node metastases; MINA 05 herbal treatment; Prostate cancer

Indexed keywords

AGAR; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN B1; MINA 05; PHOSPHATASE; PLANT EXTRACT; PLASTIC; PROTEIN CDC25C; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 34247249279     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06775     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, and Thun MJ (2005). Cancer statistics, 2005. CA Cancer J Clin 55, 10-30.
2. Engel LW and Straus SE (2002). Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov 1, 229-237.
3. Talalay P and Talalay P (2001). The importance of using scientific principles in the development of medicinal agents from plants. Acad Med 76, 238-247.
4. Hsieh TC, Lu X, Guo J, Xiong W, Kunicki J, Darzynkiewicz Z, and Wu JM (2002). Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies. Int J Oncol 20, 681-689.
5. Wang HZ, Zhang Y, Xie LP, Yu XY, and Zhang RQ (2002). Effects of genistein and daidzein on the cell growth, cell cycle, and differentiation of human and murine melanoma cells. J Nutr Biochem 13, 421-426.
6. Chen WF, Huang MH, Tzang CH, Yang M, and Wong MS (2003). Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta 1638, 187-196.
7. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, and Elgavish A (2005). Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 135, 989-995.
8. Jayaprakasam B, Seeram NP, and Nair MG (2003). Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 189, 11-16.
9. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, and Sebti SM (2005). Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24, 3236-3245.
10. Balestrieri C, Felice F, Piacente S, Pizza C, Montoro P, Oleszek W, Visciano V, and Balestrieri ML (2006). Relative effects of phenolic constituents from Yucca schidigera Roezl bark on Kaposi's sarcoma cell proliferation, migration, and PAF synthesis. Biochem Pharmacol 71, 1479-1487.
11. Carroll AG, Voeller HJ, Sugars I, and Gelmann EP (1999). p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23, 123-134.
12. Jackson P, Grimm M-O, Kingsley EA, Brosius U, Antalis T, Yardley G, and Russell PJ (2002). Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. Urol Oncol 7, 99-104.
13. Lee Y-G, Kornechuk S, Lehr J, Whitney S, Vessela R, and Pienta KJ (2003). Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 15, 157-162.
14. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, and Lucia MS (2003). Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205-225.
15. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, and Chung LW (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54, 2577-2581.
16. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, et al. (1997). Progression of metastatic human CaP to androgen independence in immunodeficient SCID mice. Nat Med 3, 402-408.
17. Stark GR and Taylor WR (2004). Analyzing the G2/M checkpoint. Methods Mol Biol 280, 51-82.
18. Draetta G and Eckstein J (1997). Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1332, M53- M63.
19. Nilsson I and Hoffman I (2000). Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4, 107-114.
20. Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS, and Piwnica-Worms H (1997). Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc35C on serine-216. Science 277, 1501-1505.
21. Lock RB and Ross WE (1990). Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res 50, 3767-3771.
22. McGowan CH (2002). Checking in on Cds 1 (Chk2): a checkpoint kinase and tumor suppressor. Bioessays 24, 502-511.
23. Smits VA, Klompmaker R, Arnaud L, Fijksen G, Nigg FA, and Medema RH (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2, 672-676.
24. Bassermann F, von Klitzing C, Munch S, Bai RY, Kawaguchi H, Morris SW, Peschel C, and Duyster J (2005). NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45-57.
25. Huang T-S, Shu C-H, Chao Y, Chen S-N, and Chen L-L (2000). Activation of MAD2 checkprotein and persistence of cyclin B1/CDC2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 5, 235-241.
26. Taylor WR and Stark GR (2001). Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815.
27. Bunz F, Dutriaux A, Lengauer C, Walkman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 82, 1497-1501.
28. Griffith TD and Tolmach LJ (1976). Lethal response of HeLa cells to X-irradiation in the latter part of the generation cycle. Biophys J 16, 303-318.